The approval of the KEYTRUDA combination for patients with primary advanced or recurrent endometrial cancer is based on results from the NRG-GY018/KEYNOTE-868 clinical trial, a Phase III study evaluating the combination of anti-PD-1 immunotherapy and chemotherapy in patients with two different tumor types.
FDA approves Merck’s Keytruda in combination with carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer
Leave a Comment
